Dyne Therapeutics (DYN) Other Non-Current Assets (2019 - 2026)
Dyne Therapeutics (DYN) recorded quarterly Other Non-Current Assets of $15.6 million in Q1 2026, little changed quarter-over-quarter from $15.6 million in Q4 2025, and up 702.73% on a YoY basis from $1.9 million in Q1 2025.
Dyne Therapeutics (DYN) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Dyne Therapeutics' Other Non-Current Assets history runs 8 years deep, the most recent figure standing at $15.6 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 702.73% year-over-year to $15.6 million; the TTM figure through Mar 2026 stood at $15.6 million (up 702.73% YoY), while the FY2025 annual figure was $15.6 million, up 703.3% from the prior year.
- Other Non-Current Assets was $15.6 million for Q1 2026 at Dyne Therapeutics, roughly flat from $15.6 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $15.6 million in Q4 2025 to a low of $1.9 million in Q1 2024.
- Historically, Other Non-Current Assets has averaged $4.5 million across 5 years, with a median of $2.3 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets slipped 17.28% in 2024, then surged 703.3% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $2.3 million in 2022, then declined by 0.17% to $2.3 million in 2023, then fell by 16.11% to $1.9 million in 2024, then soared by 703.3% to $15.6 million in 2025, then retreated by 0.07% to $15.6 million in 2026.
- The last three Other Non-Current Assets figures came in at $15.6 million (Q1 2026), $15.6 million (Q4 2025), and $15.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Dyne Therapeutics | 3.00 Bn | 3.00 Bn | - | 15.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.59 Mn |
| Dec 31, 2025 | 15.60 Mn |
| Sep 30, 2025 | 15.01 Mn |
| Jun 30, 2025 | 2.51 Mn |
| Mar 31, 2025 | 1.94 Mn |
| Dec 31, 2024 | 1.94 Mn |
| Sep 30, 2024 | 1.94 Mn |
| Jun 30, 2024 | 1.93 Mn |
| Mar 31, 2024 | 1.92 Mn |
| Dec 31, 2023 | 2.32 Mn |
| Sep 30, 2023 | 2.33 Mn |
| Jun 30, 2023 | 2.32 Mn |
| Mar 31, 2023 | 2.32 Mn |
| Dec 31, 2022 | 2.32 Mn |
| Sep 30, 2022 | 2.30 Mn |
| Jun 30, 2022 | 2.30 Mn |
| Mar 31, 2022 | 2.31 Mn |
| Dec 31, 2021 | 2.31 Mn |
| Sep 30, 2021 | 2.70 Mn |
| Jun 30, 2021 | 2.70 Mn |